Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”
Retrieved on:
Saturday, October 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Newton, Safety, CMS, Neurology, GPVI, Research, Hoffmann-La Roche, Innovation, VI, Medicine, Patient, Texas, Mediolanum, Stroke, Memorial Hermann–Texas Medical Center, Chief executive officer, Paris, Paris-Sud University, Nature, Texas Medical Center, International, Company, Mobile stroke unit, CEO, Growth, National Institute, Children's Memorial Hermann Hospital, Biotechnology, Pharmaceutical industry, glenzocimab (ACT017), the Therapeutic Candidate, glenzocimab and Stroke, Acticor Biotech, GLENZOCIMAB (ACT017), THE THERAPEUTIC CANDIDATE, GLENZOCIMAB AND STROKE, ACTICOR BIOTECH
Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
Key Points:
- Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
- This collaboration aims to prepare an international clinical trial ACTISAVE to evaluate the efficacy of glenzocimab in patients suffering from acute ischemic stroke.
- This eighth edition of the Galien Medstartup Awards was chaired by Bernard Poussot, Director of Roche Holding and former Chairman & CEO of Wyeth.
- This year again, the event featured a remarkable world-renowned panel, rewarding the most innovative projects in the healthcare industry.